Clinical Features and Progression of Parkinson's Disease with LRRK2 Variants: A Prospective Study

Overview

Journal Ann Clin Transl Neurol

Specialty Neurology

Date 2024 Nov 12

PMID 39529459

Authors

Tingwei Song

Xiaoxia Zhou

Chunyu Wang

Heng Wu

Xinxiang Yan

JiFeng Guo

Beisha Tang

Lifang Lei

Qian Xu

Affiliations

Soon will be listed here.

Abstract

Objective: We established a prospective cohort study to investigate the differences in motor and non-motor symptoms between idiopathic Parkinson's disease (IPD) and Parkinson's disease in carriers of leucine-rich repeat kinase 2 (LRRK2) gene risk variants (LRRK2-PD).

Methods: The study included 1407 individuals with IPD and 649 individuals with LRRK2-PD (comprising 304 with LRRK2-G2385R, 220 with LRRK2-R1628P, and 105 with LRRK2-A419V). Differences in symptoms between LRRK2-PD and IPD were analyzed using LCMM modeling and Cox regression analysis.

Results: The LRRK2-G2385R variant showed slower progression in tremor symptoms and excessive daytime sleepiness compared with IPD. In contrast, symptoms associated with LRRK2-R1628P and LRRK2-A419V were more similar to those of IPD. Survival analysis revealed that LRRK2-PD does not affect life expectancy compared with IPD.

Interpretation: Our extended longitudinal follow-up of LRRK2-PD in the Chinese population provided valuable insights, further confirming the clinical characteristics of the three LRRK2 variants.

References

Zhao Y, Qin L, Pan H, Liu Z, Jiang L, He Y . The role of genetics in Parkinson's disease: a large cohort study in Chinese mainland population. Brain. 2020; 143(7):2220-2234. DOI: 10.1093/brain/awaa167. View

Nabli F, Ben Sassi S, Amouri R, Duda J, Farrer M, Hentati F . Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study. Mov Disord. 2014; 30(2):253-8. DOI: 10.1002/mds.26097. View

Pan H, Liu Z, Ma J, Li Y, Zhao Y, Zhou X . Genome-wide association study using whole-genome sequencing identifies risk loci for Parkinson's disease in Chinese population. NPJ Parkinsons Dis. 2023; 9(1):22. PMC: 9911746. DOI: 10.1038/s41531-023-00456-6. View

Yu Q, Guo P, Li D, Zuo L, Lian T, Yu S . Olfactory Dysfunction and Its Relationship with Clinical Symptoms of Alzheimer Disease. Aging Dis. 2018; 9(6):1084-1095. PMC: 6284764. DOI: 10.14336/AD.2018.0819. View

Nalls M, Blauwendraat C, Vallerga C, Heilbron K, Bandres-Ciga S, Chang D . Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019; 18(12):1091-1102. PMC: 8422160. DOI: 10.1016/S1474-4422(19)30320-5. View

Bloem B, Okun M, Klein C . Parkinson's disease. Lancet. 2021; 397(10291):2284-2303. DOI: 10.1016/S0140-6736(21)00218-X. View

Oosterveld L, Allen Jr J, Ng E, Seah S, Tay K, Au W . Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology. 2015; 85(12):1039-42. DOI: 10.1212/WNL.0000000000001953. View

Sun Y, Zhou X, Liang X, Lin J, Xu Y, Chen C . The genetic spectrum of a cohort of patients clinically diagnosed as Parkinson's disease in mainland China. NPJ Parkinsons Dis. 2023; 9(1):76. PMC: 10192372. DOI: 10.1038/s41531-023-00518-9. View

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

10.

Alcalay R, Mirelman A, Saunders-Pullman R, Tang M, Mejia Santana H, Raymond D . Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord. 2013; 28(14):1966-71. PMC: 3859844. DOI: 10.1002/mds.25647. View

11.

Cui S, Fu R, Du J, Lin Y, Huang P, Gao C . Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease. BMC Neurosci. 2021; 22(1):22. PMC: 8004448. DOI: 10.1186/s12868-021-00623-6. View

12.

Johns M . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-5. DOI: 10.1093/sleep/14.6.540. View

13.

Lanore A, Casse F, Tesson C, Courtin T, Menon P, Sambin S . Differences in Survival across Monogenic Forms of Parkinson's Disease. Ann Neurol. 2023; 94(1):123-132. DOI: 10.1002/ana.26636. View

14.

Marder K, Wang Y, Alcalay R, Mejia-Santana H, Tang M, Lee A . Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology. 2015; 85(1):89-95. PMC: 4501942. DOI: 10.1212/WNL.0000000000001708. View

15.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

16.

Chen Y, Yu S, Zhang G, Hou Y, Gu X, Ou R . The mutation spectrum of Parkinson-disease-related genes in early-onset Parkinson's disease in ethnic Chinese. Eur J Neurol. 2022; 29(11):3218-3228. DOI: 10.1111/ene.15509. View

17.

Yahalom G, Orlev Y, Cohen O, Kozlova E, Friedman E, Inzelberg R . Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation. Mov Disord. 2014; 29(8):1057-60. DOI: 10.1002/mds.25931. View

18.

Shu L, Zhang Y, Pan H, Xu Q, Guo J, Tang B . Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-Analysis. Front Aging Neurosci. 2018; 10:283. PMC: 6156433. DOI: 10.3389/fnagi.2018.00283. View

19.

Liang D, Shu L, Pan H, Xu Q, Guo J, Yan X . Clinical characteristics of PD patients with LRRK2 G2385R and R1628P variants. Neurosci Lett. 2018; 685:185-189. DOI: 10.1016/j.neulet.2018.08.015. View

20.

Simuni T, Brumm M, Uribe L, Caspell-Garcia C, Coffey C, Siderowf A . Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Mov Disord. 2020; 35(5):833-844. PMC: 7231646. DOI: 10.1002/mds.27989. View